MNG510
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.628
- MYC_TARGETS_V2+0.560
- MTORC1_SIGNALING+0.470
- MYC_TARGETS_V1+0.408
- DNA_REPAIR+0.396
- UNFOLDED_PROTEIN_RESPONSE+0.371
- INTERFERON_ALPHA_RESPONSE+0.362
- ALLOGRAFT_REJECTION+0.355
- ADIPOGENESIS+0.349
- FATTY_ACID_METABOLISM+0.306
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.534
- ANGIOGENESIS-0.402
- MYOGENESIS-0.342
- COAGULATION-0.323
- UV_RESPONSE_DN-0.306
- APICAL_JUNCTION-0.280
- APICAL_SURFACE-0.261
- KRAS_SIGNALING_DN-0.247
- ESTROGEN_RESPONSE_EARLY-0.226
- HEDGEHOG_SIGNALING-0.217
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | cdef9a7f-9daa-4a33-b196-08a12a2ed203 | — | — | 0.873 |
| 2 | TCGA-66-2758-01A-02R-0851-07 | — | cohortSQ2 | 0.844 |
| 3 | TCGA-AR-A0TW-01A-11R-A084-07 | — | B | 0.842 |
| 4 | SRR17866821 | — | — | 0.841 |
| 5 | ddd65fce-1a39-415c-9114-7a9c8e9b266c | — | — | 0.837 |
| 6 | e0464181-da72-4a14-9039-a396843c39f2 | — | — | 0.834 |
| 7 | MNG277 | — | — | 0.834 |
| 8 | BS_W80TJC27 | EPN | Supratentorial EPN | 0.832 |
| 9 | MNG602 | — | — | 0.831 |
| 10 | 992ce1bc-46a2-4f57-ac7a-c6368c69c67c | — | — | 0.830 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.628 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.560 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.470 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.408 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.396 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.371 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.362 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.355 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.349 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.306 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.292 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.292 | Inavolisib | — uncovered |
| PEROXISOME | 0.277 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.258 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.247 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.216 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.206 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.163 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.153 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.141 | Idelalisib | — uncovered |